Aptahem AB (publ), a biotechnology company, engages in the development of ribonucleic acid-based pharmaceuticals in Sweden. The company’s lead product candidate is Apta-1, which is in Phase I clinical trial for the treatment of patients with sepsis/septic shock and severe inflammatory conditions, as well as to prevent organ and tissue damages in life-threatening conditions. It also develops Apta-2 which is in preclinical stage for the treatment of inflammation; and Apta-3 which is in discovery stage. The company has a collaboration with Hongene Biotech for the manufacturing of RNA and oligonucleotides. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
Metrics to compare | APTA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAPTAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.9x | −3.4x | −0.5x | |
PEG Ratio | −0.05 | −0.08 | 0.00 | |
Price/Book | 0.3x | 3.5x | 2.6x | |
Price / LTM Sales | 7.3x | 13.7x | 3.1x | |
Upside (Analyst Target) | - | 112.3% | 55.9% | |
Fair Value Upside | Unlock | 32.1% | 7.4% | Unlock |